الفهرس 
CORONAVIRUS DISEASE (COVID-19)Only 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
The SARS-COV-2 outbreak rapidly spread across the world and it has spurred a global effort to tackle the disease and to establish risk factors and prognostic markers like for example serum vitamin D. The evidence continued to grow and there are more publications in peer reviewed medical journals about the possible connection between vitamin D and SARS-COV-2.
Patients hospitalized in intensive care units (ICU) had high plasma levels of IL-2, IL-7, IL-10, GSCF, IP10, MCP1, MIP1A, and TNFα. Given the natural three-stage clinical course of the disease, inadequate innate immune response in the first stage and immune-mediated damage due to dysregulated immune response in the second stage are considered to be the major determinants of poor outcomes. Several classes of drugs and supplements, including vitamin D, are being evaluated for the treatment of COVID-19, based on the growing evidence regarding the natural history and evolution of the infection obtained from patients.
The benefits of vitamin D in patients suffering from ARDS are due to the activation of the vitamin D receptor pathway, resulting in a decrease of cytokine expression, a central cause of rapid deterioration. Additionally, vitamin D deficiency in ICU patients is common and may indicate that other complications in COVID-19 infections are the result of this deficiency.
So our study aimed to evaluate the therapeutic role of vitamin D supplement in SARS-COV-2.
We consider seven outcomes to be measured in our meta-analysis which are: Duration of COVID-19 illness till recovery, need for O2 therapy, need for ICU admission, need artificial ventilation, fatal prognosis, time to negative PCR, need for hospitalization.
Regarding the first outcome which is the duration of hospital stay, our study found that vitamin d supplement decreases the period of hospital stay in SARS-CoV2 positive patients.